Howl like a wolf (all the way to 24!!)Howl like a wolf (all the way to 24!!) . the company is working on breakthrough drug research and partnering with major pharma players
−1.05USD
−37.37 MUSD
19.94 MUSD
29.29 M
About Werewolf Therapeutics, Inc.
Sector
CEO
Daniel J. Hicklin
Headquarters
Watertown
Website
Employees (FY)
47
Founded
2017
ISIN
US95075A1079
FIGI
BBG00QXQ9XK4
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HOWL is 5.84 USD — it has increased by 4.10% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Werewolf Therapeutics, Inc. stocks are traded under the ticker HOWL.
Werewolf Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
HOWL stock is 8.83% volatile and has beta coefficient of 1.36. Check out the list of the most volatile stocks — is Werewolf Therapeutics, Inc. there?
One year price forecast for Werewolf Therapeutics, Inc. has a max estimate of 15.00 USD and a min estimate of 9.00 USD.
HOWL earnings for the last quarter are −0.23 USD whereas the estimation was −0.39 USD which accounts for 40.41% surprise. Estimated earnings for the next quarter are −0.42 USD. See more details about Werewolf Therapeutics, Inc. earnings.
Werewolf Therapeutics, Inc. revenue for the last quarter amounts to 5.90 M USD despite the estimated figure of 1.59 M USD. In the next quarter revenue is expected to reach 1.94 M USD.
Yes, you can track Werewolf Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
HOWL stock has risen by 12.09% compared to the previous week, the month change is a 6.56% fall, over the last year Werewolf Therapeutics, Inc. has showed a 134.54% increase.
No, HOWL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HOWL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Werewolf Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 47.00 employees. See our rating of the largest employees — is Werewolf Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Werewolf Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Werewolf Therapeutics, Inc. stock shows the buy signal. See more of Werewolf Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Werewolf Therapeutics, Inc. future price: according to them, HOWL price has a max estimate of 15.00 USD and a min estimate of 9.00 USD. Read a more detailed Werewolf Therapeutics, Inc. forecast: see what analysts think of Werewolf Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Werewolf Therapeutics, Inc. EBITDA is −38.06 M USD, and current EBITDA margin is −194.25%. See more stats in Werewolf Therapeutics, Inc. financial statements.